894787-93-0

Basic information

• Product Name: {(4R,6S)-6-[(E)-2-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}vinyl]-2,2-dimethyl-1,3-dioxan-4-yl}acetic acid
• Synonyms: {(4R,6S)-6-[(E)-2-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}vinyl]-2,2-dimethyl-1,3-dioxan-4-yl}acetic acid
• CAS NO: 894787-93-0
• Molecular Weight: 521.61
• Mol File: 894787-93-0.mol

Chemical Properties

• Boiling Point: 700.5±70.0 °C(Predicted)
• Density: 1.296±0.06 g/cm3(Predicted)
• CAS DataBase Reference: {(4R,6S)-6-[(E)-2-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}vinyl]-2,2-dimethyl-1,3-dioxan-4-yl}acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: {(4R,6S)-6-[(E)-2-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}vinyl]-2,2-dimethyl-1,3-dioxan-4-yl}acetic acid(894787-93-0)
• EPA Substance Registry System: {(4R,6S)-6-[(E)-2-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}vinyl]-2,2-dimethyl-1,3-dioxan-4-yl}acetic acid(894787-93-0)

Safety Data

• Hazardous Substances Data: 894787-93-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(4R,6S)-6-[(E)-2-4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-ylvinyl]-2,2-dimethyl-1,3-dioxan-4-ylacetic acid is used as a potential pharmaceutical compound for its structural complexity and the presence of functional groups that may interact with biological systems. (4R,6S)-6-[(E)-2-4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-ylvinyl]-2,2-dimethyl-1,3-dioxan-4-ylacetic acid's potential applications in the pharmaceutical industry could include the development of new drugs or therapies, targeting specific diseases or conditions.
Used in Research and Development:
In the field of research and development, (4R,6S)-6-[(E)-2-4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-ylvinyl]-2,2-dimethyl-1,3-dioxan-4-ylacetic acid can be utilized as a starting material or a key intermediate in the synthesis of other complex organic molecules. Its unique structure and functional groups make it a valuable candidate for further exploration and experimentation, potentially leading to the discovery of new compounds with novel properties and applications.
Used in Chemical Synthesis:
(4R,6S)-6-[(E)-2-4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-ylvinyl]-2,2-dimethyl-1,3-dioxan-4-ylacetic acid may also find use in chemical synthesis, particularly in the production of other complex organic compounds. Its structural features and functional groups can be exploited to create a variety of new molecules with different properties and potential applications, contributing to the advancement of the chemical industry.

Upstream product

• 289042-12-2 2-[(4R,6S)-6-[(E)-2-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidin-5-yl]vinyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid tert butyl ester 
• 851440-18-1 6-((1E)-2-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)ethenyl)-2,2-dimethyl-1,3-dioxan-4yl acetic acid ethyl ester 
• 1378943-63-5 tertiary-butyl (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]ethenyl}-(4R,6S)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
• 1263475-93-9 4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl(methyl)amino)pyrimidine-5-carboxylic acid 
• 147118-36-3 N-[4-(4-fluorophenyl)-5-(hydroxymethyl)-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide 
• 42558-54-3 Methyl 4-methyl-3-oxopentanoate 
• 953047-22-8 (2S)-1-chloropent-4-en-2-ol 
• 154026-95-6 (4R-cis)-6-[(acetyloxy)methyl]-2,2-dimethyl-1,3-dioxane-4-acetic acid tert-butyl ester 
• 799842-07-2 N-[5-(bromomethyl)-4-(4-fluorophenyl)-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide 
• 1007871-85-3 tert-butyl-6-[(1E)-2-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]ethenyl]-2,2-dimethyl-1,3-dioxane-4-acetate 
• 124752-23-4 tert-butyl 2-[(4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl]acetate 
• 124655-09-0 1,1-dimethylethyl (4R-cis)-6-hydroxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate 

Downstream Products

• 1207460-28-3 2-((4R,6S)-6-((E)-2-(4-(4'-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetic acid n-propyl amine salt 
• 894787-94-1 (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid methylamine salt 
• 915749-99-4 (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid diethanolamine salt 
• 915750-00-4 (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid ethanolamine salt 
• 915750-02-6 (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid L-lysine salt 

Relevant articles and documents

A novel process for synthesis of Rosuvastatin

A novel process for the preparation of antihypercholesterolemic drug rosuvastatin calcium using novel intermediates has been described. Novel intermediates have been characterized by using IR, NMR and Mass spectroscopy.

Stereocontrolled synthesis of rosuvastatin calcium via iodine chloride-induced intramolecular cyclization

A novel, stereoselective approach towards rosuvastatin calcium from the known (S)-homoallylic alcohol has been developed. The synthesis is highlighted by a regio- and stereocontrolled ICl-induced intramolecular cyclization of chiral homoallylic carbonate to deliver the C6-formyl statin side chain with a syn-1,3-diol moiety. An improved synthesis of the rosuvastatin pyrimidine core moiety is also included. Moreover, this methodology is useful in the asymmetric synthesis of structural variants of statins such as pitavastatin calcium and atorvastatin calcium and their related analogs.

POLYMORPHS OF ROSUVASTATIN ACETONIDE CALCIUM ((3R,5S,6E)-7-[4-(4- FLUOROPHENYL)-6-ISOPROPYL-2-(METHANESULFONYL-METHYL-AMINO)-PYRIMN)IN-5- YL)VINYL)-2,2-DIMETHYL-L,3-DIOXAN-4-YL) ACETIC ACID CALCIUM SALT

The present invention relates to crystalline forms and an amorphous form of Rosuvastatin Acetonide Calcium which is known by the systemic chemical name (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2- (methanesulfonyl-methyl-amino)pyrimidin-5-yl)vinyl)-2,2

PROCESS FOR THE PREPARATION OF ROSUVASTATIN AND INTERMEDIATES

The subject of the present invention is a process for the preparation of rosuvastatin by reacting a compound of formula II, by alkalic hydrolysis to give a compound of formula III, thereafter reacting with an organic or inorganic base to form a salt, eliminating the acetonide group and reacting with calcium-chloride in a base. A further subject of the present invention is a compound of formula III and its salts formed by organic or inorganic base.

A PROCESS FOR PREPARING HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES

The present invention relates to an improved process for synthesizing calcium salt of (E)-7-[4-(4-flurophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acid (Rosuvastatin Calcium) in high purity.